Skin melanoma: Present possibilities of treatment in Poland based on own experiences of melanoma patients' course and current review of literature;Czerniak skóry: Aktualne możliwości leczenia w Polsce na podstawie analizy leczonych pacjentów i przegladu literatury

Wspolczesna Onkologia

Volumn 10, Issue 9, 2006, Pages 437-448

  Kycler, Witold ^a   Teresiak, Marek ^a  

^a GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

Diagnostics; Melanoma; Prophylaxis; Treatment

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; DIAGNOSTIC IMAGING; DISEASE COURSE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL LITERATURE; MELANOMA; POLAND; REVIEW; SKIN MANIFESTATION; SKIN SURGERY;

EID: 33845931098     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Boni R, Schuster C, Nehrhoff B, Burg G. Epidemiology of Skin Cancer. Neuroendocrinol Lett 2002; 23 (supl. 2): 48-51.
2. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-90.
3. Godlewski D. Nowotwory złośliwe w Wielkopolsce. Agencja BAS - Biuro Analiz Społecznych 1998.
4. Didkowska J, Wojciechowska U, Tarnowski W, Zatoński W. Nowotwory złośliwe w Polsce w 1999 roku. Centrum Onkologii - Instytut Marii Skłodowskiej Curie 2002.
5. Wojciechowska U, Didkowska J, Tarnowski W, Zatoński W. Nowotwory złośliwe w Polsce w 2002 roku. Centrum Onkologii - Instytut Marii Skłodowskiej Curie 2004.
6. Ruka W. Standardy postepowania diagnostyczno-terapeutyczne. go w czerniaku skóry. W: Krzakowski M, Siedlecki P (red.). Standardy leczenia systemowego nowotworów złoliwych u dorosłych w Polsce. Grupa Multimedialna, Warszawa 1999; 89-103.
7. Cammarota T, Pinto F, Magliaro A, Sarno A. Current uses of diagnostic high frequency US in dermatology. Eur J Radiol 1998; 27:215-223.
8. Takahashi M, Kohda H. Diagnostic utility of magnetic resonance imaging in malignant melanoma. J Am Acad Dermatol 1993; 28: 513-515.
9. Gritters LS, Francis IR, Zasadny KR, Wahl RL Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34:1420-1427.
10. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
11. Balch CM, Soong SJ, Gershenwald JE, et al. rognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
12. Evans RD, Kopf AW, Lew RA, et al. Risk Factors for the development of malignant melanoma- I: review of case-control studies. J Dermatol Surg Oncol 1998; 14: 393-408.
13. Diffey BL. Sunscreen and melanoma: the future looks bright. Br J Dermatol 2005; 153: 378-81.
14. Espinosa AJ, Sanchez HJ, Bravo F, et al. Cutaneous malignant melanoma and sun exposure in Spain. Melanoma Res 1999; 9: 1999-205.
15. Moseley HS, Giuliano AE, Storm FK 3rd, et al. Multiple primary melanoma. Cancer 1979: 70: 1911-6.
16. Rigel DS, Naylor M, Robinson J. What is the evidence for a sunscreen and melanoma controversy? Arch Dermatol 2000; 136: 1447-9.
17. Rigel DS. Is the ounce of screening prevention for skin cancer worth the pound of cure? CA Cancer J Clin 1998; 48: 236-8.
18. Robinson JK, Rigel DS, Amonette RA. What promotes skin self examination? J Am Acad Dermatol 1998; 38:752-7.
19. Friedman RJ, Rigel DS, Silverman MK, et al. Malignant melanoma in the 1990s: the continued importance of early detection and role of physician examination and self-examination of the skin. CA Cancer J Clin 1991; 41:201-26.
20. Sahin S, Rao B, Kopf AW, et at. Predicting ten year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 1997; 80: 1426-31.
21. Ng AK, Jones WO, Shaw JH. Analysis of local recurrence and optimizing excision margins for cutaneous melanoma. Br J Surg 2001; 88: 137-42.
22. Towpik E (red.). Rozpoznanie kliniczne i leczenie czerniaka skóry. WHO Melanoma Programme. Wydawnictwo Polskiej Fundacji Europejskiej Szkoły Onkologii, Warszawa 1998.
23. Kycler W, Grodecka-Gazdecka S, Teresiak M, Krenz R. Wpływ wybranych cech klinicznych i morfologicznych na czas przeżycia chorych na czerniaka skóry. Współcz Onkol 2001; 5: 52-57.
24. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results and controversies. J Clin Oncol 1998; 6:163-72.
25. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69:108-1L
26. Scott RN, McKay AJ. Elective lymph node dissection in the management of malignant melanoma. Br J Surg 1993; 80:284-8.
27. Shen P, Guenter IM, Wanek LA, Morton DL Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma reccurences? Ann Surg Oncol 2000; 7: 114-9.
28. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7:469-74.
29. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14:280-90.
30. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69:108-11.
31. Murawa P, Gracz A, Nowakowski W. Wiarygodność biopsji wezła wartowniczego w leczeniu czerniaka złośliwego skóry. Post Dermatol Alergol 2001; 18:28-32.
32. Mussack T, Waldner H, Kharraz-Tavakol A. Risk factors for lymph node metastasis in malignant melanoma. Zentralbl Chir 1996; 121: 465-8.
33. Stokkel A, Bergman W, Pauwels EKJ. Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur J Nuclear Med 2000; 27:447-58.
34. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89: 453-62.
35. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
36. Cohran AJ, Balda BR, Starz H, et al. The Augsburg Consensus: Techniques of lymphatic mapping sentinel lymphadenectomy and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 6: 225-32.
37. Cohran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma: An immunohistochemical study. Am J Surg Pathol 1988; 12: 612-8.
38. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999: 17:3238-44.
39. Messina JL, Glass F. Pathologic examination of the sentinel node. J Fla Med Assoc 1997; 84:153-6.
40. Starz H, Bachter D, Balda BR, et al. Qualitative and quantitative evaluation of sentinel lymph nodes in cutaneous malignancies. Nuklearmediziner 1999; 22: 253-60.
41. Starz H, Balda BR. Sentinel lymphadenectomy and micromorphometric S-staging, a successful new strategy in the management of cutaneous malignancies. G Ital Dermatol Venereol 2000; 135: 161-9.
42. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
43. Cohran AJ, Wen DR, Herschmann JR. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 1984; 34: 163-9.
44. Huang RR, Wen DR, Guo J, et al. Modulation of paracortical dendritic cells and T lymphocytes in breast cancer sentinel nodes. Breast 2000; 89: 237-41.
45. Cohran AJ, Wen DR, Morton DL, Stern S, et al. Sentinel lymph nodes show profound down-regulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001; 14: 604-8.
46. Liszkay G, Orsz Z, Peley G, et al. Relationship between sentinel lymph node status and regression of primary malignant melanoma. Mel Res 2005; 15:509-13.
47. Starz H, Balda BR, Kramer KU, et al. A micromorphometry based concept for routine staging classification of sentinel lymph node metastases and its clinical relevance in melanoma patients. Cancer 2001; 91: 2110-21.
48. Shivers SC, Li W, Lin J, et al. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 2001; 158: 187-99.
49. Fincher TR, McCaety TM, Fisher TL, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg 2003; 186: 675-81.
50. Leong SP. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node expirence. Am J Sur Oncol 2004; 11: 192S-7S
51. Carlson GW, Murray DR, Greenlee R, et al. Management of malignant melanoma of head and neck using dynamic lymphoscintigraphy and gamma probe-guided sentinel lymph nod biopsy. Arch Otolaryngol Head Neck Surg 2000; 126: 433-7.
52. Essner R. Sentinel lymph node biopsy and melanoma biology. Clin Cancer Res 2006; 12: 2320-25.
53. Cohran AJ, Pihl E, Wen DR, et al. Zoned immune suppressiono of lymph nodes draining malignant melanoma. Histologic and immunohistologic studies. J Natl Cancer Inst 1997; 78:399-405.
54. Farzad Z, Mi Bride WH, Ogbechi H, et al. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma Res 1997; 7: 59-65.
55. Slingluff CL jr., Engelhardt VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006; 12: 2342-45.
56. Behocine TZ, Scott AM, Even-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47: 957-67.
57. Francis IR, Brown RK, Avram AM. The clinical role of CT/PET in oncology - an update. Cancer Imaging 2005; 23A: S68-75.
58. Harpole DH Jr, Jahnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc 1992; 103: 743-48.
59. Tafra L, Dale PS, Wanek LA, et al. Resection and adjuvant immunotherapy for melanoma metastatic to lung and thorax. J Thorac Cardiovasc Surg 1994; 110: 119-28.
60. Ricaniadis N, Konstadoulakis MM, Walsh D, Karakousis CP. Gastrointestinal metastasis from malignant melanoma. Surg Oncol 1995; 4: 105-10.
61. Olila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal track. Arch Surg 1996; 131: 975-80.
62. Krige JE, Nel PN, Hudson DA. Surgical treatment of metastatic melanoma of the small bowel. Am Surg 1996; 62: 658-63.
63. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903-7.
64. Vrouenrates BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83:1319-28.
65. Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906-12.
66. Hellriegel W. Radiation therapy of primary and metastatic melanoma. Ann Ny Acad Sci 1963: 100-131.
67. Wideł M. Eksperymentalne i kliniczne aspekty radiobiologii czerniaka złośliwego. Nowotwory 1996; 46: 742-760.
68. Skowronek J, Matecka-Nowak M, Nowakowska E i wsp. The role of radiotherapy in the treatment of malignant melanoma. Rep Pract Oncol Radioth 1998; 1: 3-7.
69. Skowronek J, Cerkaska-Głuszak B, Matecka-Nowak M. Wyniki paliatywnej radioterapii czerniaka złośliwego. Nowiny Lekarskie 1996; 66: 25-31.
70. Skowronek J, O'Shea A, Kubaszewska M. Wyniki leczenia napromienianiem chorych na czerniaka złośliwego w materiale Wielkopolskiego Centrum Onkologii. Współcz Onkol 1999; 2: 65-68.
71. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
72. Retsas S. Adjuvant therapy of malignant melanoma: is there a choice? Crit Rev Oncol Hematol 2001; 40:187-93.
73. Hill GJ 2nd, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 453888) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981; 47: 2556-62.
74. Aamadal S, Avril MD, Grob JJ, et al. A phase III randomized trial of fotemustine (F) versus dacarbazine (DTIC) in patients with disseminated malignant melanoma with or without brain metastases. Proc Am Soc Clin Oncol 2002; 21:136.
75. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-51.
76. Vrouenraets BC, Hart GA, Eggermont AM, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999; 188:522-30.
77. Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999; 85: 1979-84.
78. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16(5): 1743-51.
79. Gibbs P, Iannucci A, Becker M, et al. A phase II study of biochemotherapy for metastatic malignant melanoma. Melanoma Res 2000; 10: 171-9.
80. Philip PA, Flaherty LE. Biochemotherapy for Melanoma. Curr Oncol Rep 2000; 2:314-21.
81. Bernengo MG, Quaglina P, Capello N, et al. Macrophage-mediate immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res 2000; 10:55-65.
82. Daponte A, Ascierto PA, Gravina A, et al. Cisplatin, dacarbazine and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000; 89:2630-6.
83. Dillman RO, Soori G, Wiemann MC, et al. Phase II trial of subcutaneous interleukin 2, subcutaneous interferon-alpha, intravenous combination chemotherapy and oral tamoxifen in the treatment of metastatic melanoma: final result of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000; 15:487-94.
84. Hernberg M., Turunen JP, Muhonen T, Pyrhonen S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 1997; 20: 488-95.
85. Hoffmann R, Muller I, Neuber K, et al. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha 2a. Br J Cancer 1998; 78:1076-80.
86. Proebstle TM, Fuchs T, Scheibenbogen C, et al. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interieukin-2 in poor risk melanoma patients. Melanoma Res 1998; 8: 557-63.
87. Vaughan MM, Moore J, Riches PG, et al. GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. Ann Oncol 2000; 11:1183-9.
88. Falkson CI, Ibrahim J, Kirkwood JM, et al. phase III trial of dacarbazine versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-61.
89. Eilber FR, Morton DL, Holmes EC, et al. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med 1976; 294:237-40.
90. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomized trial. Lancet 2001; 358: 866-9.
91. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systemic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-25.
92. Oncologic Drugs Advisory Committee. Issues in the clinical development of investigational agents being evaluated for the post-surgical adjuvant treatment of high risk (stage IIb and III) melanoma. http://www.fda.gov/ ohrms/dockets/ac/02/slides/383851.html.2002.
93. Nawrocki S, Mackiewicz A. Terapia genowa nowotworów wyzwaniem XXI wieku. Współcz Onkol 2000; 4: 190-4.
94. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. I Clin Oncol 2002; 20: 2067-75.
95. Morton DL, Hsuch EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with a Canvaxin. Ann Surg 2002; 236: 438-48.
96. Sondack VK, Liu Py, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20: 2058-66.
97. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III randomized, double-blind, multicenter vaccine melanoma oncological trial. J Am Coll Surg 1998; 187: 69-79.
98. Davis N. Modern concepts of melanoma and its management. Ann Plast Surg 1978; 1: 628-9.